Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabigatran vs Different Intensity Warfarin in Non-valvular Atrial Fibrillation
NCT02646267Phase 4Unknown
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Mar 2016
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dabigatran etexilate oral solution in Atrial fibrillation (AFib) (3 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoints: Ischaemic stroke at 2 years and Major haemorrhage at 2 years. Status: unknown.
02
Drugs
dabigatran etexilate oral solution
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT02646267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02646267.